期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

氟达拉滨联合环磷酰胺治疗慢性淋巴细胞白血病疗效观察 被引量：4

下载PDF
导出
摘要 目的研究氟达拉滨联合环磷酰胺(FC方案)治疗慢性淋巴细胞白血病的近期疗效和副反应。方法回顾性对照分析FC方案和环磷酰胺联合长春新碱、阿霉素、强的松(CHOP方案)治疗成人慢性淋巴细胞白血病(CLL)的疗效及副反应。结果 FC方案组与CHOP方案组完全缓解率分别是34.8%和18.2%(P>0.05),总有效率分别为87.0%和54.5%(P<0.05)。两组方案对WBC、PLT的抑制程度以及副反应方面,两组方案差异无统计学意义。结论 FC方案诱导治疗成人CLL的完全缓解率和总有效率均高于CHOP方案.其中总有效率两组方案差异有统计学意义(P<0.05);两组方案副反应差异无统计学意义,FC方案可以作为成人CLL患者一线化疗方案。
作者 涂金明 郭小媛 沈卫华 王庆军 周卫锦 罗方
机构地区 浙江省龙游县人民医院血液内科
出处 《海峡药学》 2011年第3期132-133,共2页 Strait Pharmaceutical Journal
关键词 氟达拉滨 环磷酰胺 慢性淋巴细胞白血病
分类号 R969.4 [医药卫生—药理学]
  • 相关文献

参考文献12

  • 1Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of flu-darabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients [J] . Blood, 2001, 98 : 2319- 2325.
  • 2Barbara F, Eiehhorst, Raymonde B, et al. Fludarabine plus cyclophos- phamide versus fludarabine alone in first-line therapy of younger pa- tients with chronic lyre phocytic leukemia[J]. Blood, 2006, 107:885.
  • 3Montillo M, Ricci F, Tedeschi A. Role of fludarabine in hematological ma 1 ignancies [J] . Expert Rev Anticancer Ther, 2006, 6 ( 9 ) : 1141.
  • 4刘红,江渝,陈幸华,孔佩艳,张怡,刘林,张曦,王庆余.氟达拉滨联合化疗药物治疗14例复发、难治性非霍奇金淋巴瘤临床疗效分析[J].重庆医学,2005,34(5):708-710. 被引量：5
  • 5张之南.血液病诊断及疗敖标准[M].第3版.北京:科学出版社.2007,139.
  • 6Grever MR, Kopeeky K.H, Coltman CA, et al. Fludarabine monophos- phate:A potentially useful agent in chronic lymphocytic leukemia [J]. Nouv Rev Fr Henmtol, 1988, 30:457-459.
  • 7O'Brien S, Kantarjian H, Beran M, et al. RESULTS of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis derived prognostic model for response totreatment [J] . Blood, 1993 82 : 1695.
  • 8Adkins JC, Peters DH, Markham A, et al. An update of its pharmacol- ogy and use in the treatment of haematologlcal malignancies [J].Drugs, 1997, 53 : 1005.
  • 9Keating M J, O Brien S, Lemer S, et al. Long term follow-up of Pal tients with chronic lymphocytic leukemia(CLL) receiving fludarabin1 regimens asinitial therapy [J]. Blood, 1998, 92:1165.
  • 100' Brien S, Kaatarjian H, Cortes J, et al. Results of the fludarahineand cyclophosphamide combination regimen in chronic lymdhocytic leukemia[J] .J Clin Oncol, 2001, 19 : 1414-1420.

二级参考文献10

  • 1田怀平,卜书红,李方.氟达拉宾的药物学及应用[J].北京医学,2004,26(5):351-353. 被引量：4
  • 2Gregory SA,Vose J,Modiano M ,et al. Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen[J]. Leuk Lymphoma,2001,40(3-4) : 315.
  • 3Mclaughin P, Hagemeister FB, Romaguera JE, et al. Fludarabine mitoxantrone, and dexamethasone., an effective new regimen for indolent lymphoma[J]. J Clin Oncol,1996,14(4) : 1262.
  • 4Santini G,Nati S,Spriano M,et al. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma [J]. Haematologica, 2001,86(3) :282.
  • 5Herold M, Sacchi S, Hieke K. The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use[J].Haematologica,2002,87(7) : 719.
  • 6张之南.血液病诊断及疗效标准[M].北京：科学出版社,1999.270-271.
  • 7Gandhi V, Plunkett W. Cellular and clinical pharmacology of Fara-A. Clin Pharmacokinet ,2002,41:93103.
  • 8Tallrnan MS, Hakirnian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood, 1995,86:2463.
  • 9Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med,2000,343:1750.
  • 10Leporrier M,Chevret S, Cazin B,et aL Randomized comparison of fludarabine,CAP,and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood, 2001,98:2319.

共引文献9

同被引文献10

引证文献4

二级引证文献1

海峡药学
2011年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部